Achillion is an innovative biopharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company's highly skilled and experienced discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease - HCV and resistant bacterial infections.

Achillion's approach in developing new therapies for HCV is multi-fold: First, Achillion is advancing a proprietary compound that targets the HCV NS3 protease, sovaprevir (ACH-1625), a potent HCV inhibitor with an excellent safety profile, unique pharmacokinetics and once-daily dosing. Second, Achillion is advancing ACH-2684, a compound with excellent potency in the pico-molar range focused on emerging resistant HCV variants. Third, Achillion is developing NS5A inhibitors that possess pan-genotypic activity and picomolar potency including ACH-3102, a second-generation NS5A inhibitor in Phase 2 development that has pan-genotypic, pico-molar potency and enhanced in vitro activity against resistant mutants.

Achillion sees significant competitive advantages in developing anti-infective drugs compared to developing drugs in other therapeutic areas. The emergence of drug resistance seen with current antiviral and antibacterial therapies creates a continuing need for new drugs, providing a large and growing potential business opportunity. In addition, development cycle times tend to be somewhat shorter in infectious disease than other therapeutic areas, and early drug development results tend to be more predictive of longer term results.